These drugs block the action of calcineurin, thus preventing the transcription of interleukin-2 (IL-2) and other cytokines, which are essential for T-cell activation. By inhibiting this pathway, calcineurin inhibitors reduce the immune system's ability to attack its own tissues, making them useful in the treatment of autoimmune diseases.
